Recently in pharma news, in a 9 – 0 ruling, the U.S. Supreme Court overturned a lower court’s decision that prevented Novartis from selling its biosimilar version of Neupogen, a drug made by California-based Amgen Inc. Prior to the ruling, biosimilar drugs (also referred to as “copycat” versions of other drugs) could not be put on the market until six …

It’s no secret that pharmaceutical drug prices continue to soar, however recent news reports have revealed that some of the major health insurance companies are choosing to pay drug makers per negotiated contracts based on patients’ outcomes, as value-based care becomes more prominent in the pharmaceutical industry. Some of the major players using the value-based model include Cigna, Aetna, Blue …

On May 25, FDA Commissioner Scott Gottlieb told House lawmakers that the Food and Drug Administration intends to take steps to lower drug prices by increasing generic drug competition. Gottlieb announced the FDA hiring freeze placed on the agency by the Trump administration is over, and that the FDA will have clear and more frequent communication with developers of generic …